Datta Souvik, Lin Feng, Jones Lawrence D, Pingle Sandeep C, Kesari Santosh, Ashili Shashaanka
Rhenix Lifesciences, 237 Arsha Apartments, Kalyan Nagar, Hyderabad, TG 500038, India.
CureScience, 5820 Oberlin Drive #202, San Diego, CA 92121, USA.
Future Sci OA. 2023 May 9;9(6):FSO864. doi: 10.2144/fsoa-2023-0037. eCollection 2023 Jul.
Traumatic brain injury (TBI) is a significant cause of mortality and morbidity worldwide resulting from falls, car accidents, sports, and blast injuries. TBI is characterized by severe, life-threatening consequences due to neuroinflammation in the brain. Contact and collision sports lead to higher disability and death rates among young adults. Unfortunately, no therapy or drug protocol currently addresses the complex pathophysiology of TBI, leading to the long-term chronic neuroinflammatory assaults. However, the immune response plays a crucial role in tissue-level injury repair. This review aims to provide a better understanding of TBI's immunobiology and management protocols from an immunopathological perspective. It further elaborates on the risk factors, disease outcomes, and preclinical studies to design precisely targeted interventions for enhancing TBI outcomes.
创伤性脑损伤(TBI)是全球范围内因跌倒、车祸、运动和爆炸伤导致死亡和发病的重要原因。TBI的特征是由于脑部神经炎症而导致严重的、危及生命的后果。接触性和碰撞性运动在年轻人中导致更高的残疾率和死亡率。不幸的是,目前没有治疗方法或药物方案能够解决TBI复杂的病理生理学问题,从而导致长期的慢性神经炎症侵袭。然而,免疫反应在组织水平的损伤修复中起着关键作用。本综述旨在从免疫病理学角度更好地理解TBI的免疫生物学和管理方案。它进一步阐述了风险因素、疾病结局和临床前研究,以设计精确靶向的干预措施来改善TBI的治疗效果。